Clinical Trial Update: Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ruxolitinib versus best available therapy in patients with polycythemia vera resistant or intolerant to hydroxyurea; results posted afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polycythemia Vera | Phase 3 | Status: COMPLETED | Results posted: 2021-07-20